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ABSTRACT 
OnabotulinumtoxinA intradetrusor injections are considered a highly effective localized therapy for 
refractory DO. However, despite evidence for distant systemic effects of onabotulinumtoxinA, little is 
known on potential systemic side effects following intradetrusor injections. Given that 
onabotulinumtoxinA is a highly potent toxin this is an important safety issue specifically with regard to 
repeat injections and parallel treatments with BoNT/A. Hence, it was the purpose of this prospective 
study to investigate, using heart rate variability (HRV) analysis, whether onabotulinumtoxinA causes 
systemic effects on cardiac function following intradetrusor injections. 
Patients with NDO and age-matched healthy controls were recruited. Concomitant medication and 
diseases affecting the cardio-vascular system were exclusion criteria. A 3-channel resting 
electrocardiogram (ECG) was recorded in supine position for 15 min during four consecutive visits: 1) 
two weeks prior onabotulinumtoxinA intradetrusor injections, 2) 10min prior injections, 3) 30 min after 
injections, and 4) 6 weeks after injections. NDO patients received intradetrusor injections (300 units 
Botox®) between visits 2 and 3. The control group had no intervention. 
Short-term (5 min) HRV analysis included assessment of frequency and time domain parameters. 
Statistical analysis was performed using ANOVA with repeated measures and the t-test. Due to 
multiple comparisons, α was corrected to 0.0125 (Bonferroni method). 
Twelve healthy volunteers (5♀, 7♂; 46 ± 12 years old) and 12 NDO patients (5♀, 7♂; 46± 13 years 
old) completed all measurements. Comparing both groups, resting heart rate was significantly higher 
in the patients group at visit 4 only. No further significant differences in time and frequency domain 
parameters were discovered. 
Within the NDO group, standard deviation of the normal to normal intervals (SDNN) in the ECG 
demonstrated a significant decrease (1.70 to 1.53ms, p=0.003) from visit 3 to 4, whereas the total 
power (TP) significantly increased (3.05 to 3.29 ms2, p = 0.009) from visit 2 to 3. This increase 
subsided until visit 4. 
Study limitations: single treatment investigation under resting conditions only. 
In conclusion, onabotulinumtoxinA intradetrusor injections do not seem to affect resting state cardiac 
function. Short-term changes such as total power might rather result from natural cardio-vascular 
responses to the procedure itself (e.g. discomfort, stress). Further detailed investigations also under 
physical stress and repeated injections are necessary to fully exclude systemic cardiac side effects of 
onabotulinumtoxinA intradetrusor injections.  
 
Key words: autonomic cardiac function; botulinum toxin; heart rate variability; intradetrusor injections; 
neurogenic detrusor overactivity; onabotulinumtoxinA; spinal cord injury; systemic side effects  
Mehnert U Effects of OnabotulinumtoxinA on cardiac function following intradetrusor injections Exp Neurol 2016 
INTRODUCTION 
DO is a urodynamic finding that can be the underlying cause of bothersome LUTS such as urinary 
urgency and / or incontinence. Furthermore, DO may cause irreversible alterations to morphology and 
function of the urinary tract, including in its worst case renal failure [1]. First line treatment of DO is 
usually with antimuscarinics and just recently also a β3 adrenergic receptor agonist has been 
approved for this indication [1]. 
However, antimuscarinics and / or β3 adrenergic receptor agonists might not be sufficient to 
adequately reduce DO. In such cases, a second line treatment option is onabotulinumtoxinA 
intradetrusor injections [1]. The efficacy of onabotulinumtoxinA intradetrusor injections has been 
proven previously and the safety profile seems to be beneficial [2, 3]. However, most studies reporting 
on safety concentrated on adverse events related to the injection procedure itself, i.e. UTI, bleeding, 
pain, or the local effects on the bladder, i.e. urinary retention. Distant effects after intradetrusor 
injections have not yet been reported or investigated systematically [4]. 
However, there is evidence that BoNT/A causes effects related but not necessarily limited to its action 
on cholinergic nerve terminals elsewhere in the body than at the site of injection [5, 6]. One important 
neuromuscular structure that might be affected by distant effects following injection of BoNT/A is the 
heart [7-11]. By blocking acetylcholine release form the autonomic nerve terminals, BoNT/A can affect 
1) parasympathetic control on the sinoatrial and atrioventricular node of the heart through the vagal 
nerve [12] and 2) the preganglionic sympathetic innervation of the heart [11, 13]. Both, sympathetic 
and parasympathetic influence on the heart can be assessed using HRV analysis. During normal 
sinus rhythm, the heart rate physiologically varies from beat to beat as a result of the dynamic 
interplay between the multiple physiologic mechanisms that regulate the instantaneous heart rate [14]. 
HRV reflects the ability of the cardio-vascular system to rapidly adapt to changing needs in response 
to a broad range of internal and external stimuli and conditions and thus, is a measure of cardiac and 
overall health [15]. A reduced HRV has been associated with a poor prognosis of cardio-vascular 
disease, an increased risk of incident myocardial infarction, cardiovascular mortality, and death from 
other causes in the general population [16]. 
Considering that onabotulinumtoxinA is a highly potent neurotoxin and that leakage into the circulation 
cannot be prevented or excluded during intradetrusor injections, it was the purpose of this study to 
investigate the potential effects of onabotulinumtoxinA on cardiac function after intradetrusor injections 
using HRV assessment. 
From the anticholinergic mechanism of onabotulinumtoxinA and previous findings [7, 9, 10, 12, 17, 
18], we would expect a reduced HRV following interdetrusor injection. 
 
SUBJECTS AND METHODS 
This is a prospective, controlled, single center study. The study was performed according to the 
declaration of Helsinki, approved by the local ethics committee and registered at 
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https://www.clinicaltrials.gov (NCT identifier: NCT01337024). All subjects provided written informed 
consent prior to study inclusion. 
 
SUBJECTS 
Patients with NDO eligible for treatment with onabotulinumtoxinA intradetrusor injections and age 
matched (±5 years) healthy controls were recruited. 
Inclusion criteria for patients: age ≥ 18 years, urodynamically proven NDO refractory to antimuscarinic 
treatment. Inclusion criteria for healthy subjects: age ≥ 18 years, good physical and mental health. 
 
Table 1 Demographic data of patients with neurogenic detrusor overactivity and age-matched healthy control subjects. 
Patient / Subject 
No. – Gender – Age 
[years] 
Neurological 
lesion / disease 
ASIA impairment 
scale / level of 
lesion 
Duration of 
lesion / disease 
[years] 
1 – M – 36 Spinal cord inury A / Th5 18 
2 – M – 39 Spinal cord inury A / Th6 17 
3 – F – 43 Multiple sclerosis - 21 
4 – M – 43 Spinal cord inury A / Th5 4 
5 – M – 38 Spinal cord inury A / Th6 8 
6 – F – 71 Spinal cord inury A / Th3 24 
7 – M – 51 Spinal cord inury C / Th4 7 
8 – F – 47 Spinal cord inury C / L4 3 
9 – M – 63 Spinal cord inury D / C1 3 
10 – F – 58 Multiple sclerosis - 33 
11 – F – 38 Spinal cord inury A / L2 27 
12 – M – 22 Meningomyelocele  22 
    
Healthy controls    
1 – M – 35 None - - 
2 – M – 34 None - - 
3 – F – 48 None - - 
4 – M – 48 None - - 
5 – F – 41 None - - 
6 – M – 67 None - - 
7 – M – 51 None - - 
8 – F – 50 None - - 
9 – M – 62 None - - 
10 – M – 54 None - - 
11 – F – 36 None - - 
12 – F – 27 None - - 
ASIA American Spinal Injury Association, C cervical, L lumbar, Th thoracic 
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Exclusion criteria: pregnancy or lactation, any diseases of the cardiovascular system (e.g. cardiac 
arrhythmia, myocardial infarction, surgery), as well as cardiac pacemaker and medication with impact 
to cardiac function (e.g. beta-blockers, antiarrhythmic drugs), and medication influencing thyroid 
function; use of antimuscarinic therapy within 10 days prior to the first measurement; previous BoNT/A 
treatment within the last 12 months prior to the first measurement. 
Additional exclusion criteria for healthy subjects only: any current health problem or concomitant 
medication. 
 
ELECTROCARDIOGRAM (ECG) RECORDINGS 
The measurements were performed in a quiet separate examination room at constant room 
temperature and each subject / patient had a 30 – 35 min rest period to adjust to environment and 
setting. All subjects / patients were instructed to avoid caffeine, smoking, and meals at least 2 h before 
measurements. 
Just prior to each measurement, subjects / patients were instructed to refrain from closing their eyes, 
moving or talking, or to intentionally control breathing. 
Subsequently, a 3-channel resting ECG was recorded in a comfortable supine position with empty 
bladder for 15 minutes during four consecutive visits: 1) 2 weeks prior to onabotulinumtoxinA 
intradetrusor injections, 2) 10 min prior to injections, 3) 30 min after injections, and 4) 6 weeks after 
injections. 
To reduce a confounding effect of pain from the onabotulinumtoxinA injection procedure on the HRV 
measurement, all patients rated their pain level on a VAS before and after injection treatment. Only 
when the post-injection pain VAS score reached the baseline value, the post-injection ECG was 
recorded. 
The healthy control group had their ECG recordings at identical time intervals. The recordings of each 
subject / patient were performed at the same day times as the initial recording (visit 1). 
 
ONABOTULINUMTOXINA INTRADETRUSOR INJECTIONS 
All included patients with NDO received 300 units onabotulinumtoxinA (Botox®) diluted in 30 mL 
saline and injected at 30 different sites sparing the trigone using a rigid or flexible cystoscope as 
described previously [19]. 
Local intravesical anesthesia was applied with 60 mL buffered lidocaine solution (30 mL of 2% 
lidocaine and 30 mL of 8.4% sodium bicarbonate) instilled 15 – 20 minutes prior to 
onabotulinumtoxinA injection. 
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Table 2 Heart rate variability outcome parameters (mean ±SD) from all 4 consecutive visits of both groups, patients undergoing 
onabotulinumtoxinA (onaBTA) intradetrusor injections for treatment of neurogenic detrusor overactivity (n = 12) and age-
matched healthy controls (HC, n = 12). All HRV parameters were generated from 5-minutes time intervals and, except resting 
heart rate (rHR), log10 transformed. The p-values result from a t-test analysis between both groups. Due to multiple 
comparisons α was corrected to 0.0125 for all values (Bonferroni method). 
 
 
rHR 
[bpm] 
VLF 
[ms
2
] 
LF 
[ms
2
] 
HF 
[ms
2
] 
LF/HF 
TP 
[ms
2
] 
RMSS
D 
[ms] 
SDNN 
[ms] 
V
is
it
 1
 
ona-BTA 
71 
±15 
2.46  
±0.4 
2.50  
±0.4 
2.29  
±0.6 
1.13  
±0.2 
2.96  
±0.4 
1.45  
±0.4 
1.59  
±0.3 
HC 
65 
±10 
2.55  
±0.4 
2.37  
±0.4 
2.32  
±0.4 
1.03  
±0.1 
2.95  
±0.4 
1.39  
±0.3 
1.53  
±0.2 
p value 0.203 0.608 0.413 0.876 0.16 0.974 0.707 0.584 
V
is
it
 2
 
ona-BTA 
73 
±17 
2.66  
±0.3 
2.51  
±0.5 
2.27  
±0.6 
1.15  
±0.2 
3.05  
±0.4 
1.49  
±0.4 
1.65  
±0.2 
HC 
62 
±9 
2.56  
±0.3 
2.54  
±0.4 
2.33  
±0.5 
1.12  
±0.2 
3.00  
±0.3 
1.41  
±0.2 
1.57  
±0.2 
p value 0.062 0.489 0.857 0.808 0.79 0.769 0.552 0.316 
V
is
it
 3
 
ona-BTA 
69 
±14 
2.90  
±0.4 
2.77  
±0.4 
2.51  
±0.6 
1.13  
±0.2 
3.29  
±0.3 
1.57  
±0.3 
1.70  
±0.1 
HC 
60 
±8 
2.61  
±0.3 
2.49  
±0.4 
2.42  
±0.5 
1.04  
±0.2 
3.05  
±0.3 
1.53  
±0.3 
1.64  
±0.2 
p value 0.074 0.053 0.131 0.674 0.247 0.046 0.795 0.454 
V
is
it
 4
 
ona-BTA 
73 
±10 
2.63  
±0.4 
2.42  
±0.5 
2.12  
±0.7 
1.18  
±0.2 
3.04  
±0.4 
1.32  
±0.3 
1.53  
±0.2 
HC 
61 
±9 
2.80  
±0.4 
2.55  
±0.5 
2.46  
±0.5 
1.05  
±0.2 
3.22  
±0.4 
1.51  
±0.3 
1.62  
±0.2 
p value 0.004 0.312 0.575 0.181 0.073 0.257 0.134 0.278 
HC healthy controls, HF high frequency, LF low frequency, LF/HF low frequency / high 
frequency ratio, onaBTA onabotulinumtoxinA, rHR resting heart rate, RMSSD Root Mean 
Square of the Successive Differences, SDNN standard deviation of the NN intervals, TP total 
power, VLF very low frequency. 
 
HRV ANALYSIS 
From the 15 minutes ECG recording, the middle 5 minutes were used for HRV analysis which was 
performed using SOLEASY™(Alea Solutions, Zürich, Switzerland) as follows: a) detection of r-waves 
in the ECG, b) calculation of the RR intervals and generation of discrete event series (DES), c) 
calculation of power spectra from DES d) calculation of the integral of very low frequency (VLF), low 
frequency (LF) and high frequency (HF) ranges. From these frequency domain parameters the total 
power (TP = VLF + LF + HF) and the LF/HF ratio were calculated. 
For the time domain analysis, the mean heart rate at rest (rHR), the standard deviation of the normal 
to normal (NN or RR, i.e. interval between two R peaks) intervals (SDNN), and the root mean square 
of the sum of differences between adjacent NN intervals (RMSSD) were calculated. 
For more details and background on HRV previous publications elsewhere are recommended [14, 15, 
20]. 
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OUTCOME MEASURES 
The primary outcome parameter was TP, as a general indicator for both, sympathetic and 
parasympathetic autonomic nervous system activity on the heart. 
Secondary outcome parameters were VLF, LF, HF, LF/HF, rHR, RMSSD, and SDNN. 
 
 
Figure 1 Total power (TP, in ms
2
) during the four consecutive visits for the control (blue bars) 
and the neurogenic detrusor overactivity (NDO, grey bars) group. In the NDO group, there 
was a significant (*p = 0.009) increase in TP from visit 2 to 3 and significant (#p = 0.003) 
decrease from visit 3 to 4. 
 
 
STATISTICAL ANALYSIS 
All data, except rHR, were log10 transformed. Statistical analysis was performed using IBM SPSS 
Statistics 17.0 and ANOVA with repeated measures to analyse differences within each group, i.e. 
between visits, and the t-test to analyse differences between both groups. Due to multiple 
comparisons, α was corrected to 0.0125 (Bonferroni method). All values are presented as mean ± 
standard deviation (SD).  
 
 
RESULTS 
Twelve patients with NDO (46 ± 13 years old; 5 females, 7 males) and 12 healthy subjects (46 ± 12 
years old; 5 females, 7males) were included and completed all investigations (Table 1). The cause of 
NDO was SCI (n = 9), MS (n = 2), and spina bifida (n= 1) (Table 1). 
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Figure 2 Root mean square of the successive differences (RMSSD, in ms) and standard 
deviation of NN intervals (SDNN, in ms) during the four consecutive visits for the control (blue 
bars) and the neurogenic detrusor overactivity (NDO, grey bars) group. In the NDO group, 
SDNN decreased significantly (#p = 0.003) from visit 3 to 4. 
 
HRV PARAMETERS 
Within the control group there were no significant changes of any HRV parameter throughout the four 
visits. 
Within the NDO patient group there was a significant increase (p= 0.009) in TP from visit 2 to 3 and a 
significant decrease (p=0.003) from visit 3 to 4 (Table 2, Figure 1). The SDNN parameter decreased 
significantly (p=0.003) from visit 3 to 4 (Table 2, Figure 2). There were no further significant changes 
of HRV parameters throughout the four visits. 
Comparing both groups during all visits revealed a significant difference (p=0.004) in rHR at visit 4 
(Table 2, Figure 3). There were no further significant differences of HRV parameters between groups 
(Table 2, Figure 2, Figure 4, Figure 5). 
 
DISCUSSION 
The main findings of this study are a temporary increase of TP and decrease of SDNN following 
onabotulinumtoxinA whereas rHR demonstrated a generally higher level in patients than in healthy 
controls. All other HRV parameters, i.e. VLF, LF, HF, LF/HF, RMSSD, did not show differences 
between visits, i.e. before vs after onabotulinumtoxinA injections, or groups. 
Considering previous findings from studies on the effect of botulinum toxin on the cardiac autonomic 
function [7, 10, 17, 18, 21-23], effects seem to be predominantly HRV depressive, i.e. decrease in 
coefficient of variation of heart rate [7], R-R interval variation [21], RMSSD [10, 18, 23], TP [10], and 
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SDNN [10, 17, 18], and / or parasympatholytic [12, 24], i.e. increase in rHR [10, 18, 22, 23] and 
decrease of parasympathetic related test outcomes such as 30:15 ratio [17, 22], E/I ratio [10, 17, 22], 
and Valsalva ratio [17, 22]. In line with that, animal studies in dogs demonstrated a significant 
reduction and even elimination of parasympathetic related bradycardia and atrial fibrillation, 
respectively, following BoNT/A injections into pericardial fat pads [11, 13]. An attenuation of 
parasympathetic modulation on the heart has also been described in studies on the autonomic cardiac 
effects of botulism, reporting significant declines of parasympathetic test parameters that lasted longer 
than in sympathetic tests [17], elevated rHR, and LF/HF ratio [22]. 
 
 
Figure 3 Resting heart rate (rHT, in bpm) during the four consecutive visits for the control (blue 
bars) and the neurogenic detrusor overactivity (NDO, grey bars) group. Comparing the control 
versus the NDO group, there was a significant difference (#p = 0.004) in rHR at visit 4. 
 
However, there is also a study reporting significant bradycardia after high dose intravenous BoNT/A 
application in different animals, i.e. mice, rats, rabbits, and dogs, with electrocardiogram alterations 
across all species indicating conduction defects, i.e. prolongation of the P-R, QRS, and Q-T intervals. 
In dogs, bilateral vagotomy and / or atropine could not prevent the bradycardia and ECG changes [9]. 
In addition, bradycardia and ECG changes were also observed in the isolated animal hearts, 
suggesting on the one hand that those effects are independent from respiratory related conditions and 
on the other hand that botulinum toxin A seems to act on local cardiac conducting structures such as 
artrioventricular junction, His bundle, and Purkinje fibers [9]. 
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Figure 4 Low frequency spectrum (LF, in ms
2
) and high frequency spectrum (HF, in ms
2
) during 
the four consecutive visits for the control (blue bars) and the neurogenic detrusor overactivity 
(NDO, grey bars) group. 
 
In our study we could not observe such HRV reductive and / or parasympatholytic effects as described 
previously, despite investigating resting conditions only under which vagal tone prevails and variations 
in heart rate are largely dependent on vagal modulation [20] which would then be specifically 
susceptible to attenuation by BoNT/A. 
In contrary, the observed temporary increase in TP from visit 2 to 3 in the patient / onabotulinumtoxinA 
group would rather indicate an increase in HRV since TP constitutes from the sum of the frequency 
domain parameters VLF, LF, and HF and reflects the overall autonomic activity on the heart including 
sympathetic (main contributor to the LF component) as well as parasympathetic (main contributor to 
the HF component) cardiac modulation [14, 15]. In this context it is noteworthy that, although not 
significantly, the mean values of VLF, LF, and HF increased from visit 2 to 3 in the patient group 
suggesting a rather uniform than a single component driven change of TP. In their sum, such 
insignificant changes of all frequency domain parameters might contribute to the eventually statistically 
significant outcome of TP. In addition, TP values were not different between patient and control group 
and compared to normative values from subjects of the same age group [25] the TP values of our 
patients fluctuated within a normative range. Hence, attributing this temporary change in TP to an 
effect of onabotulinumtoxinA appears rather unlikely. 
A confounding factor that can affect HRV and might contribute to the observed transient TP changes 
shortly after onabotulinumtoxinA injections is the use of the lidocaine based local anesthesia prior to 
the injections. However, lidocaine causes very different and quite opposite changes of HRV than 
isolated TP increase [26, 27], making an effect of lidocaine in this context unlikely. 
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The significant decrease in SDNN could be related to the onabotulinumtoxinA treatment. However, 
looking at the values, significance mainly results form a preceding SDNN increase until visit 3 that 
returns just below baseline value at visit 1 without significant difference to the baseline value. 
The significant difference between groups in rHR at visit 4 results most probably from the continuously 
higher rHR in the patient group compared to the healthy control group which nearly became already 
significant at visit 2. Slight rHR decrease in the control group and slight rHR increase in the patient 
group at visit 4 were sufficient to cause the statistical significance whereas each group demonstrated 
a quite stable rHR throughout all visits. Since most patients suffered from SCI, the higher rHR in the 
patient group might be a consequence of the altered autonomic nervous system function in such 
patients [28]. 
In summary, we did not find relevant HRV changes related to onabotulinumtoxinA intradetrusor 
injections neither within the treated patient group nor in comparison with the untreated age-matched 
healthy control group. To the best of our knowledge, this is the first study on the relationship of 
onabotulinumtoxinA intradetrusor injections and autonomic cardiac control. There are some studies 
that investigated the effect of BoNT/A on cardiac autonomic function using HRV before and after 
injections for the treatment of cervical dystonia [7, 8, 10, 29, 30], spastic hemiplegia [31], and other 
dystonic conditions [8, 10]. However, the results are conflicting on weather BoNT/A injections have an 
effect on autonomic cardiovascular function [7, 8, 10] or not [29-31]. Comparison amongst studies 
remains very difficult and needs to be done with caution due to the different injection doses, injection 
sites, BoNT/A formulations, and primary HRV endpoints used. Moreover, time point of HRV 
assessment in relation to BoNT/A injections as well as the course of treatment, i.e. single primary 
treatment vs. chronic repeated treatment might be additional and essential factors influencing study 
outcome. Post treatment measurements followed mainly within 10 days to 6 weeks after BoNT/A 
injections. 
In our study we re-assessed the patients 6 weeks after onabotulinumtoxinA injections since this is the 
usual interval within which onabotulinumtoxinA is expected to show full efficacy on the detrusor. 
However, an earlier occurrence of transient effects might be missed whereas 30 min after 
onabotulinumtoxinA (visit 3) might be too early to observe any onabotulinumtoxinA related effects [8, 
32]. Regarding the treatment course, our patients had previous onabotulinumtoxinA treatments but not 
within 12 months prior to the first HRV measurement. Nevertheless, we cannot fully exclude a 
sustained onabotulinumtoxinA effect on autonomic cardiac control from previous injections. In this 
context it is noteworthy that in two of three studies, that demonstrated effects of BoNT/A on HRV, only 
treatment naive patients were included (in the third study, patient status was not indicated) [7, 8] 
although short-term (14–45 days) re-injections were necessary to record significant effects. This might 
suggest on the one hand a dose dependent effect of BoNT/A on cardiac autonomic control and on the 
other hand that patients with repeat BoNT/A injections might no longer show acute effects on HRV 
potentially due to an already altered baseline. In contrary, Nebe et al. investigated treatment naive 
patients only as well but did not find any BoNT/A effect on HRV [29]. Moreover, in our patient group, 
potential chronic adaptations of the cardiac autonomic control due to previously repeated 
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onabotulinumtoxinA injections must be subtle enough not to result in any difference compared to the 
healthy control group. 
Despite using a quite high dosage of 300 units onabotulinumtoxinA compared to the studies indicating 
BoNT/A effects on HRV (20–130 units onabotulinumtoxinA or 500 units abobotulinumtoxinA), we could 
not confirm effects of onabotulinumtoxinA on HRV which is in line with the most recent study on this 
topic using 600 units of incobotulinumtoxinA for treatment of spastic hemiplegia in stroke survivors 
without significant post treatment effects on HRV [31]. A possible explanation could be a less 
extensive spread of onabotulinumtoxinA after intradetrusor injections compared to injections into 
striated muscle as suggested by a pilot study of Schnitzler et al. using single fiber electromyography to 
assess the neuromuscular jitter as sign of distant neuromuscular effects in 21 patients after 300 units 
onabotulinumtoxinA intradetrusor injections for NDO [33]. 
In view of the rather sparse body of literature in contrast to the many unclarified aspects on distant 
effects of BoNT/A after injection treatments further investigations on this topic are indicated to improve 
the knowledge and patient safety regarding side effects of one of the most potent neurotoxins, that is 
frequently used in neurorehabilitation. 
Limitations of the study are: A) Focus on resting state HRV investigations only. Assessment of 
cardiovascular parameters under functional tasks such as tilt or exercise might have revealed different 
results. B) Investigation of single treatment only. No conclusions possible on the effect of repeated 
injections which might have altered the outcome of HRV measurements, specifically if performed at 
short intervals, i.e. ≤3 months. C) Post-treatment assessment of onabotulinumtoxinA effects on HRV 
at only two time points. 
 
 
Figure 5 Low frequency/high frequency (LF/HF) ratio and very low frequency spectrum (VLF, in 
ms
2
) during the four consecutive visits for the control (blue bars) and the neurogenic detrusor 
overactivity (NDO, grey bars) group. 
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In conclusion, this is the first study assessing the effects of onabotulinumtoxinA intradetrusor injections 
on autonomic cardiac function including 4 visits (two before and two after treatment) to control for 
natural fluctuations in HRV and using a healthy control group. 
Our findings indicate that onabotulinumtoxinA intradetrusor injections (300 units Botox®) do not affect 
the resting autonomic nervous system control of cardiac function. This is highly relevant in regard to 
treatment of DO in patients with altered autonomic cardiac control and might influence the choice of 
treatment in regard to alternative treatments with systemic side effects on the heart [34]. Studies 
including HRV measurements under physical stress and after repeated onabotulinumtoxinA 
intradetrusor injections are desirable future tasks.  
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